Cargando…
DNA Vaccines—How Far From Clinical Use?
Two decades ago successful transfection of antigen presenting cells (APC) in vivo was demonstrated which resulted in the induction of primary adaptive immune responses. Due to the good biocompatibility of plasmid DNA, their cost-efficient production and long shelf life, many researchers aimed to dev...
Autores principales: | Hobernik, Dominika, Bros, Matthias |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6274812/ https://www.ncbi.nlm.nih.gov/pubmed/30445702 http://dx.doi.org/10.3390/ijms19113605 |
Ejemplares similares
-
Immunocontraceptives: How far from reality?
por: Lekhwani, Seema, et al.
Publicado: (2014) -
Surface Enhanced Raman Spectroscopy for DNA Biosensors—How Far Are We?
por: Pyrak, Edyta, et al.
Publicado: (2019) -
Imaging of the unstable plaque: how far have we got?
por: Matter, Christian M., et al.
Publicado: (2009) -
The AQP2 mutation V71M causes nephrogenic diabetes insipidus in humans but does not impair the function of a bacterial homolog
por: Klein, Noreen, et al.
Publicado: (2015) -
Opportunities and Challenges in Tunneling Nanotubes Research: How Far from Clinical Application?
por: Han, Xiaoning, et al.
Publicado: (2021)